25 XP   0   0   10

Glenmark Pharmaceuticals Limited
Buy, Hold or Sell?

Let's analyse Glenmark Pharmaceuticals Limited together

PenkeI guess you are interested in Glenmark Pharmaceuticals Limited. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Glenmark Pharmaceuticals Limited. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Glenmark Pharmaceuticals Limited

I send you an email if I find something interesting about Glenmark Pharmaceuticals Limited.

Quick analysis of Glenmark Pharmaceuticals Limited (30 sec.)










What can you expect buying and holding a share of Glenmark Pharmaceuticals Limited? (30 sec.)

How much money do you get?

How much money do you get?
INR0.23
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
INR348.68
Expected worth in 1 year
INR405.54
How sure are you?
100.0%

+ What do you gain per year?

Total Gains per Share
INR76.23
Return On Investment
7.1%

For what price can you sell your share?

Current Price per Share
INR1,070.95
Expected price per share
INR883.00 - INR
How sure are you?
50%

1. Valuation of Glenmark Pharmaceuticals Limited (5 min.)




Live pricePrice per Share (EOD)

INR1,070.95

Intrinsic Value Per Share

INR-151.29 - INR49.42

Total Value Per Share

INR197.38 - INR398.10

2. Growth of Glenmark Pharmaceuticals Limited (5 min.)




Is Glenmark Pharmaceuticals Limited growing?

Current yearPrevious yearGrowGrow %
How rich?$1.1b$1.1b$48.1m4.1%

How much money is Glenmark Pharmaceuticals Limited making?

Current yearPrevious yearGrowGrow %
Making money$35.6m$113m-$77.3m-216.8%
Net Profit Margin2.3%7.7%--

How much money comes from the company's main activities?

3. Financial Health of Glenmark Pharmaceuticals Limited (5 min.)




What can you expect buying and holding a share of Glenmark Pharmaceuticals Limited? (5 min.)

Welcome investor! Glenmark Pharmaceuticals Limited's management wants to use your money to grow the business. In return you get a share of Glenmark Pharmaceuticals Limited.

What can you expect buying and holding a share of Glenmark Pharmaceuticals Limited?

First you should know what it really means to hold a share of Glenmark Pharmaceuticals Limited. And how you can make/lose money.

Speculation

The Price per Share of Glenmark Pharmaceuticals Limited is INR1,071. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Glenmark Pharmaceuticals Limited.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Glenmark Pharmaceuticals Limited, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is INR348.68. Based on the TTM, the Book Value Change Per Share is INR14.22 per quarter. Based on the YOY, the Book Value Change Per Share is INR84.12 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is INR4.84 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Glenmark Pharmaceuticals Limited.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 INR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per Share
Usd Eps0.130.0%0.130.0%0.400.0%0.330.0%0.310.0%
Usd Book Value Change Per Share0.170.0%0.170.0%1.010.1%0.360.0%0.300.0%
Usd Dividend Per Share0.060.0%0.060.0%0.040.0%0.040.0%0.030.0%
Usd Total Gains Per Share0.230.0%0.230.0%1.050.1%0.400.0%0.330.0%
Usd Price Per Share5.57-5.57-5.29-5.33-6.88-
Price to Earnings Ratio44.10-44.10-13.22-19.59-25.04-
Price-to-Total Gains Ratio24.38-24.38-5.05-24.07-57.85-
Price to Book Ratio1.33-1.33-1.32-1.70-3.39-
Price-to-Total Gains Ratio24.38-24.38-5.05-24.07-57.85-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share12.8514
Number of shares77
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.060.04
Usd Book Value Change Per Share0.170.36
Usd Total Gains Per Share0.230.40
Gains per Quarter (77 shares)17.6130.69
Gains per Year (77 shares)70.43122.78
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
118536011111113
23610513023223236
35415820034334359
47221027046445482
58926334057557605
610731541069668728
712536848080779851
814342055091891974
916147362010310021097
1017952569011411141220

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%20.00.00.0100.0%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%19.01.00.095.0%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%19.00.01.095.0%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%19.01.00.095.0%

Fundamentals of Glenmark Pharmaceuticals Limited

About Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, Japan, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, and oncology; and various active pharmaceutical ingredients. Its product pipeline includes ISB 2001, a BCMA x CD38 x CD3 trispecific antibody, which is in Phase 1 clinical trial for oncology; GRC 39815, a retinoid-related orphan receptor gamma t inverse agonist, which is in Phase 1 clinical trial for the treatment of chronic obstructive pulmonary disease; and GRC 54276, a hematopoietic progenitor kinase 1 inhibitor, which is in Phase 1 clinical trial for the treatment of solid tumors. Its pipeline also comprises ISB 1342, CD38 X CD3 bispecific antibody, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma; ISB 1442, a CD38 x CD47 immune cell engager, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma; ISB 880, a IL-1RAP antibody, which is in Phase 1 clinical trial for the treatment of autoimmune diseases; and ISB 830, a OX40 antagonist, which is in Phase 2 clinical trial for the treatment of atopic dermatitis. In addition, the company offers Ryaltris nasal spray for the treatment of seasonal allergic rhinitis. Glenmark Pharmaceuticals Limited was incorporated in 1977 and is based in Mumbai, India.

Fundamental data was last updated by Penke on 2024-04-21 20:07:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Glenmark Pharmaceuticals Limited.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Glenmark Pharmaceuticals Limited earns for each ₹1 of revenue.

  • Above 10% is considered healthy but always compare Glenmark Pharmaceuticals Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 2.3% means that ₹0.02 for each ₹1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Glenmark Pharmaceuticals Limited:

  • The MRQ is 2.3%. The company is making a profit. +1
  • The TTM is 2.3%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ2.3%TTM2.3%0.0%
TTM2.3%YOY7.7%-5.4%
TTM2.3%5Y7.1%-4.8%
5Y7.1%10Y8.0%-0.9%
1.1.2. Return on Assets

Shows how efficient Glenmark Pharmaceuticals Limited is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Glenmark Pharmaceuticals Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • 1.5% Return on Assets means that Glenmark Pharmaceuticals Limited generated ₹0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Glenmark Pharmaceuticals Limited:

  • The MRQ is 1.5%. Using its assets, the company is less efficient in making profit.
  • The TTM is 1.5%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ1.5%TTM1.5%0.0%
TTM1.5%YOY5.5%-4.0%
TTM1.5%5Y5.0%-3.5%
5Y5.0%10Y5.6%-0.6%
1.1.3. Return on Equity

Shows how efficient Glenmark Pharmaceuticals Limited is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Glenmark Pharmaceuticals Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • 3.1% Return on Equity means Glenmark Pharmaceuticals Limited generated ₹0.03 for each ₹1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Glenmark Pharmaceuticals Limited:

  • The MRQ is 3.1%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 3.1%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ3.1%TTM3.1%0.0%
TTM3.1%YOY10.4%-7.2%
TTM3.1%5Y11.0%-7.8%
5Y11.0%10Y13.8%-2.8%

1.2. Operating Efficiency of Glenmark Pharmaceuticals Limited.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Glenmark Pharmaceuticals Limited is operating .

  • Measures how much profit Glenmark Pharmaceuticals Limited makes for each ₹1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Glenmark Pharmaceuticals Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 15.6% means the company generated ₹0.16  for each ₹1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Glenmark Pharmaceuticals Limited:

  • The MRQ is 15.6%. The company is operating efficient. +1
  • The TTM is 15.6%. The company is operating efficient. +1
Trends
Current periodCompared to+/- 
MRQ15.6%TTM15.6%0.0%
TTM15.6%YOY16.5%-0.9%
TTM15.6%5Y14.9%+0.7%
5Y14.9%10Y14.9%0.0%
1.2.2. Operating Ratio

Measures how efficient Glenmark Pharmaceuticals Limited is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 0.87 means that the operating costs are ₹0.87 for each ₹1 in net sales.

Let's take a look of the Operating Ratio trends of Glenmark Pharmaceuticals Limited:

  • The MRQ is 0.869. The company is less efficient in keeping operating costs low.
  • The TTM is 0.869. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.869TTM0.8690.000
TTM0.869YOY0.849+0.020
TTM0.8695Y0.866+0.003
5Y0.86610Y0.858+0.008

1.3. Liquidity of Glenmark Pharmaceuticals Limited.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Glenmark Pharmaceuticals Limited is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.96 means the company has ₹1.96 in assets for each ₹1 in short-term debts.

Let's take a look of the Current Ratio trends of Glenmark Pharmaceuticals Limited:

  • The MRQ is 1.957. The company is able to pay all its short-term debts. +1
  • The TTM is 1.957. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.957TTM1.9570.000
TTM1.957YOY1.766+0.191
TTM1.9575Y1.758+0.199
5Y1.75810Y1.798-0.040
1.3.2. Quick Ratio

Measures if Glenmark Pharmaceuticals Limited is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Glenmark Pharmaceuticals Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 1.18 means the company can pay off ₹1.18 for each ₹1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Glenmark Pharmaceuticals Limited:

  • The MRQ is 1.178. The company is just able to pay all its short-term debts with the most liquid assets.
  • The TTM is 1.178. The company is just able to pay all its short-term debts with the most liquid assets.
Trends
Current periodCompared to+/- 
MRQ1.178TTM1.1780.000
TTM1.178YOY0.976+0.202
TTM1.1785Y1.011+0.167
5Y1.01110Y1.146-0.134

1.4. Solvency of Glenmark Pharmaceuticals Limited.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Glenmark Pharmaceuticals Limited assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Glenmark Pharmaceuticals Limited to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.49 means that Glenmark Pharmaceuticals Limited assets are financed with 49.2% credit (debt) and the remaining percentage (100% - 49.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Glenmark Pharmaceuticals Limited:

  • The MRQ is 0.492. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.492. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.492TTM0.4920.000
TTM0.492YOY0.448+0.045
TTM0.4925Y0.527-0.035
5Y0.52710Y0.576-0.049
1.4.2. Debt to Equity Ratio

Measures if Glenmark Pharmaceuticals Limited is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Glenmark Pharmaceuticals Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 100.6% means that company has ₹1.01 debt for each ₹1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Glenmark Pharmaceuticals Limited:

  • The MRQ is 1.006. The company is able to pay all its debts with equity. +1
  • The TTM is 1.006. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.006TTM1.0060.000
TTM1.006YOY0.841+0.165
TTM1.0065Y1.151-0.145
5Y1.15110Y1.428-0.276

2. Market Valuation of Glenmark Pharmaceuticals Limited

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₹1 in earnings Glenmark Pharmaceuticals Limited generates.

  • Above 15 is considered overpriced but always compare Glenmark Pharmaceuticals Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 44.10 means the investor is paying ₹44.10 for every ₹1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Glenmark Pharmaceuticals Limited:

  • The EOD is 101.670. Based on the earnings, the company is expensive. -2
  • The MRQ is 44.097. Based on the earnings, the company is overpriced. -1
  • The TTM is 44.097. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD101.670MRQ44.097+57.573
MRQ44.097TTM44.0970.000
TTM44.097YOY13.221+30.876
TTM44.0975Y19.592+24.505
5Y19.59210Y25.036-5.444
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Glenmark Pharmaceuticals Limited:

  • The EOD is 1,714.273. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is 743.527. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 743.527. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD1,714.273MRQ743.527+970.747
MRQ743.527TTM743.5270.000
TTM743.527YOY39.086+704.441
TTM743.5275Y208.228+535.299
5Y208.22810Y44.480+163.748
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Glenmark Pharmaceuticals Limited is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 1.33 means the investor is paying ₹1.33 for each ₹1 in book value.

Let's take a look of the Price to Book Ratio trends of Glenmark Pharmaceuticals Limited:

  • The EOD is 3.071. Based on the equity, the company is fair priced.
  • The MRQ is 1.332. Based on the equity, the company is underpriced. +1
  • The TTM is 1.332. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD3.071MRQ1.332+1.739
MRQ1.332TTM1.3320.000
TTM1.332YOY1.319+0.013
TTM1.3325Y1.699-0.367
5Y1.69910Y3.393-1.694
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Glenmark Pharmaceuticals Limited compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--14.21514.2150%84.123-83%30.128-53%24.990-43%
Book Value Per Share--348.677348.6770%334.462+4%272.206+28%209.787+66%
Current Ratio--1.9571.9570%1.766+11%1.758+11%1.798+9%
Debt To Asset Ratio--0.4920.4920%0.448+10%0.527-7%0.576-15%
Debt To Equity Ratio--1.0061.0060%0.841+20%1.151-13%1.428-30%
Dividend Per Share--4.8414.8410%3.285+47%3.091+57%2.716+78%
Eps--10.53410.5340%33.372-68%27.712-62%26.044-60%
Free Cash Flow Per Share--0.6250.6250%11.288-94%8.793-93%5.748-89%
Free Cash Flow To Equity Per Share---2.120-2.1200%-7.157+238%-6.963+228%0.968-319%
Gross Profit Margin---2.883-2.8830%0.048-6079%-0.546-81%-0.242-92%
Intrinsic Value_10Y_max--49.425--------
Intrinsic Value_10Y_min---151.294--------
Intrinsic Value_1Y_max--7.983--------
Intrinsic Value_1Y_min--0.481--------
Intrinsic Value_3Y_max--21.676--------
Intrinsic Value_3Y_min---12.093--------
Intrinsic Value_5Y_max--32.586--------
Intrinsic Value_5Y_min---39.410--------
Market Cap302209238600.000+57%131076326000.000131076326000.0000%124501345600.000+5%125302759520.000+5%161793126396.000-19%
Net Profit Margin--0.0230.0230%0.077-70%0.071-67%0.080-71%
Operating Margin--0.1560.1560%0.165-5%0.149+5%0.149+4%
Operating Ratio--0.8690.8690%0.849+2%0.866+0%0.858+1%
Pb Ratio3.071+57%1.3321.3320%1.319+1%1.699-22%3.393-61%
Pe Ratio101.670+57%44.09744.0970%13.221+234%19.592+125%25.036+76%
Price Per Share1070.950+57%464.500464.5000%441.200+5%444.040+5%573.330-19%
Price To Free Cash Flow Ratio1714.273+57%743.527743.5270%39.086+1802%208.228+257%44.480+1572%
Price To Total Gains Ratio56.199+57%24.37524.3750%5.048+383%24.065+1%57.854-58%
Quick Ratio--1.1781.1780%0.976+21%1.011+16%1.146+3%
Return On Assets--0.0150.0150%0.055-72%0.050-69%0.056-73%
Return On Equity--0.0310.0310%0.104-70%0.110-71%0.138-77%
Total Gains Per Share--19.05619.0560%87.408-78%33.220-43%27.706-31%
Usd Book Value--1180711080.0001180711080.0000%1132574400.000+4%921758856.000+28%710411544.000+66%
Usd Book Value Change Per Share--0.1710.1710%1.009-83%0.362-53%0.300-43%
Usd Book Value Per Share--4.1844.1840%4.014+4%3.266+28%2.517+66%
Usd Dividend Per Share--0.0580.0580%0.039+47%0.037+57%0.033+78%
Usd Eps--0.1260.1260%0.400-68%0.333-62%0.313-60%
Usd Free Cash Flow--2115480.0002115480.0000%38224200.000-94%29775816.000-93%19464624.000-89%
Usd Free Cash Flow Per Share--0.0070.0070%0.135-94%0.106-93%0.069-89%
Usd Free Cash Flow To Equity Per Share---0.025-0.0250%-0.086+238%-0.084+228%0.012-319%
Usd Market Cap3626510863.200+57%1572915912.0001572915912.0000%1494016147.200+5%1503633114.240+5%1941517516.752-19%
Usd Price Per Share12.851+57%5.5745.5740%5.294+5%5.328+5%6.880-19%
Usd Profit--35669400.00035669400.0000%113005320.000-68%93038952.000-62%87437568.000-59%
Usd Revenue--1527051960.0001527051960.0000%1460903760.000+5%1339391256.000+14%1122762708.000+36%
Usd Total Gains Per Share--0.2290.2290%1.049-78%0.399-43%0.332-31%
 EOD+4 -4MRQTTM+0 -0YOY+14 -225Y+18 -1810Y+13 -23

3.2. Fundamental Score

Let's check the fundamental score of Glenmark Pharmaceuticals Limited based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15101.670
Price to Book Ratio (EOD)Between0-13.071
Net Profit Margin (MRQ)Greater than00.023
Operating Margin (MRQ)Greater than00.156
Quick Ratio (MRQ)Greater than11.178
Current Ratio (MRQ)Greater than11.957
Debt to Asset Ratio (MRQ)Less than10.492
Debt to Equity Ratio (MRQ)Less than11.006
Return on Equity (MRQ)Greater than0.150.031
Return on Assets (MRQ)Greater than0.050.015
Total5/10 (50.0%)

3.3. Technical Score

Let's check the technical score of Glenmark Pharmaceuticals Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5069.479
Ma 20Greater thanMa 501,015.818
Ma 50Greater thanMa 100948.454
Ma 100Greater thanMa 200901.572
OpenGreater thanClose1,036.000
Total4/5 (80.0%)



Latest Balance Sheet

Balance Sheet of 2023-03-31. Currency in INR. All numbers in thousands.

Summary
Total Assets193,716,760
Total Liabilities95,324,170
Total Stockholder Equity94,739,230
 As reported
Total Liabilities 95,324,170
Total Stockholder Equity+ 94,739,230
Total Assets = 193,716,760

Assets

Total Assets193,716,760
Total Current Assets98,737,190
Long-term Assets94,979,570
Total Current Assets
Cash And Cash Equivalents 14,430,260
Short-term Investments 2,006,790
Net Receivables 40,986,060
Inventory 29,777,910
Other Current Assets 11,536,170
Total Current Assets  (as reported)98,737,190
Total Current Assets  (calculated)98,737,190
+/-0
Long-term Assets
Property Plant Equipment 50,193,410
Goodwill 736,190
Intangible Assets 23,606,830
Other Assets 19,597,700
Long-term Assets  (as reported)94,979,570
Long-term Assets  (calculated)94,134,130
+/- 845,440

Liabilities & Shareholders' Equity

Total Current Liabilities50,455,300
Long-term Liabilities44,868,870
Total Stockholder Equity94,739,230
Total Current Liabilities
Short-term Debt 5,808,860
Short Long Term Debt 4,955,820
Accounts payable 23,918,610
Other Current Liabilities 1,948,050
Total Current Liabilities  (as reported)50,455,300
Total Current Liabilities  (calculated)36,631,340
+/- 13,823,960
Long-term Liabilities
Long term Debt Total 40,463,520
Capital Lease Obligations 2,795,180
Long-term Liabilities Other 13,290
Long-term Liabilities  (as reported)44,868,870
Long-term Liabilities  (calculated)43,271,990
+/- 1,596,880
Total Stockholder Equity
Common Stock282,170
Retained Earnings 94,570,390
Accumulated Other Comprehensive Income -16,966,930
Capital Surplus 16,853,600
Total Stockholder Equity (as reported)94,739,230
Total Stockholder Equity (calculated)94,739,230
+/-0
Other
Capital Stock282,170
Cash and Short Term Investments 16,437,050
Common Stock Shares Outstanding 282,168
Current Deferred Revenue18,779,780
Liabilities and Stockholders Equity 193,716,760
Net Debt 31,842,120
Net Invested Capital 138,216,430
Net Working Capital 48,281,890
Property Plant and Equipment Gross 50,193,410
Short Long Term Debt Total 46,272,380



Balance Sheet

Currency in INR. All numbers in thousands.

 Trend2023-03-312022-03-312021-03-312020-03-312019-03-312018-03-312017-03-312016-03-312015-03-312014-03-312013-03-312012-03-312011-03-312010-03-312009-03-312008-03-312007-03-312006-03-312005-03-312004-03-31
> Total Assets 
4,557,354
9,172,705
13,512,572
19,438,551
29,455,632
42,574,624
48,837,533
50,977,770
58,834,270
71,710,030
86,336,030
96,875,060
111,026,360
122,119,710
130,209,550
136,788,380
146,848,070
156,035,770
170,832,880
193,716,760
193,716,760170,832,880156,035,770146,848,070136,788,380130,209,550122,119,710111,026,36096,875,06086,336,03071,710,03058,834,27050,977,77048,837,53342,574,62429,455,63219,438,55113,512,5729,172,7054,557,354
   > Total Current Assets 
2,610,139
5,421,214
7,414,844
11,054,332
16,510,009
20,791,381
24,210,666
25,987,690
29,471,530
37,492,830
47,626,940
53,232,740
59,096,250
68,746,380
69,886,920
66,968,250
68,036,160
73,595,790
82,823,480
98,737,190
98,737,19082,823,48073,595,79068,036,16066,968,25069,886,92068,746,38059,096,25053,232,74047,626,94037,492,83029,471,53025,987,69024,210,66620,791,38116,510,00911,054,3327,414,8445,421,2142,610,139
       Cash And Cash Equivalents 
81,255
1,272,755
1,055,984
1,057,549
1,565,069
714,823
1,070,200
1,948,720
3,200,760
6,051,850
7,947,990
7,637,350
8,571,210
10,563,640
12,333,560
9,362,780
11,102,750
11,380,950
14,105,260
14,430,260
14,430,26014,105,26011,380,95011,102,7509,362,78012,333,56010,563,6408,571,2107,637,3507,947,9906,051,8503,200,7601,948,7201,070,200714,8231,565,0691,057,5491,055,9841,272,75581,255
       Short-term Investments 
0
0
0
0
0
0
0
0
0
141,890
148,150
107,680
146,860
-514,610
1,792,460
1,968,720
696,560
763,990
328,750
2,006,790
2,006,790328,750763,990696,5601,968,7201,792,460-514,610146,860107,680148,150141,890000000000
       Net Receivables 
0
0
0
0
8,068,517
9,553,428
10,782,779
11,986,620
13,004,140
0
30,202,100
27,324,270
33,721,680
35,212,100
30,431,590
30,776,950
24,089,620
25,720,550
31,011,350
40,986,060
40,986,06031,011,35025,720,55024,089,62030,776,95030,431,59035,212,10033,721,68027,324,27030,202,100013,004,14011,986,62010,782,7799,553,4288,068,5170000
       Inventory 
821,601
1,194,215
1,575,305
2,697,092
4,007,391
6,302,253
7,084,591
8,070,120
7,876,700
8,435,320
9,328,790
12,690,390
15,677,600
21,390,490
20,305,850
22,520,740
21,356,240
22,768,330
24,998,330
29,777,910
29,777,91024,998,33022,768,33021,356,24022,520,74020,305,85021,390,49015,677,60012,690,3909,328,7908,435,3207,876,7008,070,1207,084,5916,302,2534,007,3912,697,0921,575,3051,194,215821,601
       Other Current Assets 
1,707,283
2,954,244
4,783,555
7,299,691
2,869,032
4,220,877
5,273,096
3,982,230
5,389,930
22,863,770
-90
32,797,320
978,900
1,580,150
35,455,050
33,116,010
11,405,680
12,275,500
2,770,970
11,536,170
11,536,1702,770,97012,275,50011,405,68033,116,01035,455,0501,580,150978,90032,797,320-9022,863,7705,389,9303,982,2305,273,0964,220,8772,869,0327,299,6914,783,5552,954,2441,707,283
   > Long-term Assets 
1,947,215
3,751,491
6,097,728
8,384,219
12,945,623
21,783,243
24,626,867
24,990,080
29,362,740
34,217,200
38,709,090
43,642,320
51,930,110
53,373,330
60,322,630
69,820,130
78,811,910
82,439,980
88,009,400
94,979,570
94,979,57088,009,40082,439,98078,811,91069,820,13060,322,63053,373,33051,930,11043,642,32038,709,09034,217,20029,362,74024,990,08024,626,86721,783,24312,945,6238,384,2196,097,7283,751,4911,947,215
       Property Plant Equipment 
1,741,507
3,502,835
5,804,653
8,104,284
12,557,427
13,310,876
15,253,108
11,794,120
12,994,520
15,546,380
17,628,130
20,569,490
24,622,850
27,451,480
32,080,890
36,397,230
40,929,010
42,035,420
46,535,500
50,193,410
50,193,41046,535,50042,035,42040,929,01036,397,23032,080,89027,451,48024,622,85020,569,49017,628,13015,546,38012,994,52011,794,12015,253,10813,310,87612,557,4278,104,2845,804,6533,502,8351,741,507
       Goodwill 
0
0
0
0
0
563,783
660,573
605,700
608,640
603,660
602,040
579,700
574,800
478,920
521,040
547,350
528,990
580,110
600,190
736,190
736,190600,190580,110528,990547,350521,040478,920574,800579,700602,040603,660608,640605,700660,573563,78300000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
183,660
171,180
281,630
243,330
234,640
798,460
0
0
0
0
0000798,460234,640243,330281,630171,180183,6600000000000
       Intangible Assets 
0
0
0
0
0
7,241,866
7,967,097
9,723,380
11,253,070
12,135,710
12,728,760
12,134,930
14,452,420
12,855,810
14,581,790
18,935,660
21,291,980
22,769,380
22,253,790
23,606,830
23,606,83022,253,79022,769,38021,291,98018,935,66014,581,79012,855,81014,452,42012,134,93012,728,76012,135,71011,253,0709,723,3807,967,0977,241,86600000
       Long-term Assets Other 
177,555
171,678
213,099
187,237
188,171
181,229
181,229
309,220
332,310
179,050
354,770
370,310
337,490
1,280
2,583,000
585,740
997,550
1,189,440
1,202,050
1,910,470
1,910,4701,202,0501,189,440997,550585,7402,583,0001,280337,490370,310354,770179,050332,310309,220181,229181,229188,171187,237213,099171,678177,555
> Total Liabilities 
2,209,352
5,883,086
9,581,477
12,574,901
14,262,107
26,561,508
25,155,125
30,338,390
34,567,990
43,836,140
56,370,430
66,873,570
68,326,910
72,729,660
74,322,710
76,839,840
86,146,940
85,393,040
76,451,680
95,324,170
95,324,17076,451,68085,393,04086,146,94076,839,84074,322,71072,729,66068,326,91066,873,57056,370,43043,836,14034,567,99030,338,39025,155,12526,561,50814,262,10712,574,9019,581,4775,883,0862,209,352
   > Total Current Liabilities 
767,428
1,122,203
1,727,511
2,395,148
3,207,174
4,563,295
5,186,210
22,518,580
19,017,420
21,804,850
29,491,660
37,112,900
40,017,620
27,038,840
32,878,930
40,210,940
41,259,830
42,010,200
46,894,310
50,455,300
50,455,30046,894,31042,010,20041,259,83040,210,94032,878,93027,038,84040,017,62037,112,90029,491,66021,804,85019,017,42022,518,5805,186,2104,563,2953,207,1742,395,1481,727,5111,122,203767,428
       Short-term Debt 
0
0
0
0
0
0
0
14,913,960
9,320,310
8,445,730
8,383,110
12,255,520
15,008,090
1,873,190
4,976,070
8,749,140
9,116,370
8,728,660
11,902,830
5,808,860
5,808,86011,902,8308,728,6609,116,3708,749,1404,976,0701,873,19015,008,09012,255,5208,383,1108,445,7309,320,31014,913,9600000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
32,669,720
8,779,520
7,133,910
1,873,190
4,976,070
8,749,140
8,256,400
5,130,150
10,986,050
4,955,820
4,955,82010,986,0505,130,1508,256,4008,749,1404,976,0701,873,1907,133,9108,779,52032,669,7200000000000
       Accounts payable 
0
0
0
0
0
3,434,779
2,971,576
6,574,060
7,888,290
10,375,570
13,625,840
20,456,670
20,065,790
19,035,320
18,697,840
22,207,510
21,258,430
22,377,680
22,886,620
23,918,610
23,918,61022,886,62022,377,68021,258,43022,207,51018,697,84019,035,32020,065,79020,456,67013,625,84010,375,5707,888,2906,574,0602,971,5763,434,77900000
       Other Current Liabilities 
767,428
1,122,203
1,727,511
2,395,148
3,207,174
1,128,516
2,214,634
919,880
1,445,930
1,443,410
328,210
770,130
594,210
1,770,640
145,840
157,370
393,630
286,380
122,190
1,948,050
1,948,050122,190286,380393,630157,370145,8401,770,640594,210770,130328,2101,443,4101,445,930919,8802,214,6341,128,5163,207,1742,395,1481,727,5111,122,203767,428
   > Long-term Liabilities 
1,441,924
4,760,883
7,853,966
10,179,753
11,054,933
21,998,213
19,968,915
7,819,810
15,550,570
22,031,290
26,878,770
29,760,670
28,309,290
45,690,820
41,443,780
36,628,900
44,887,110
43,382,840
29,557,370
44,868,870
44,868,87029,557,37043,382,84044,887,11036,628,90041,443,78045,690,82028,309,29029,760,67026,878,77022,031,29015,550,5707,819,81019,968,91521,998,21311,054,93310,179,7537,853,9664,760,8831,441,924
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
24,872,970
45,363,390
41,417,780
35,737,540
42,743,370
41,128,510
27,717,380
40,463,520
40,463,52027,717,38041,128,51042,743,37035,737,54041,417,78045,363,39024,872,970000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
2,592,160
4,016,870
769,900
327,430
26,000
959,920
2,143,740
2,254,330
1,839,990
0
01,839,9902,254,3302,143,740959,92026,000327,430769,9004,016,8702,592,1600000000000
> Total Stockholder Equity
2,343,637
3,289,619
3,931,095
6,863,650
15,178,729
15,981,564
23,552,333
20,372,370
24,016,300
27,630,250
29,832,800
30,003,360
42,702,460
49,394,280
55,890,540
59,952,310
60,705,050
70,646,270
90,866,470
94,739,230
94,739,23090,866,47070,646,27060,705,05059,952,31055,890,54049,394,28042,702,46030,003,36029,832,80027,630,25024,016,30020,372,37023,552,33315,981,56415,178,7296,863,6503,931,0953,289,6192,343,637
   Common Stock
218,546
437,286
437,486
240,116
248,726
250,520
269,838
270,270
270,530
270,850
271,220
271,310
282,160
282,170
282,170
282,170
282,170
282,170
282,170
282,170
282,170282,170282,170282,170282,170282,170282,170282,160271,310271,220270,850270,530270,270269,838250,520248,726240,116437,486437,286218,546
   Retained Earnings Total Equity00000000000000000000
   Accumulated Other Comprehensive Income -16,966,930-18,378,370-18,825,680-13,806,630-11,218,170-9,377,780-7,870,560-6,605,960-5,619,050-4,746,310-3,769,600-2,980,410-2,151,660-1,882,552-1,347,389-2,055,881-1,165,094-768,296-518,175-349,176
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
17,293,470
17,296,100
17,296,100
16,853,600
16,853,600
16,853,600
16,853,600
16,853,600
16,853,60016,853,60016,853,60016,853,60016,853,60017,296,10017,296,10017,293,470000000000000
   Treasury Stock00000000000000000000
   Other Stockholders Equity 
2,474,267
3,370,508
4,261,905
7,788,628
16,985,884
17,078,433
25,165,047
8,854,640
9,086,040
8,459,520
7,311,910
4,624,230
11,654,770
11,163,270
12,064,960
-57,886,960
-4,329,030
-1,972,080
-2,979,900
-113,330
-113,330-2,979,900-1,972,080-4,329,030-57,886,96012,064,96011,163,27011,654,7704,624,2307,311,9108,459,5209,086,0408,854,64025,165,04717,078,43316,985,8847,788,6284,261,9053,370,5082,474,267



Balance Sheet

Currency in INR. All numbers in thousands.




Cash Flow

Currency in INR. All numbers in thousands.




Income Statement

Currency in INR. All numbers in thousands.


Latest Income Statement (annual, 2023-03-31)

Gross Profit (+$)
totalRevenue127,254,330
Cost of Revenue-45,369,540
Gross Profit81,884,79081,884,790
 
Operating Income (+$)
Gross Profit81,884,790
Operating Expense-65,213,770
Operating Income16,671,02016,671,020
 
Operating Expense (+$)
Research Development12,500,350
Selling General Administrative3,039,990
Selling And Marketing Expenses11,541,040
Operating Expense65,213,77027,081,380
 
Net Interest Income (+$)
Interest Income3,495,830
Interest Expense-3,495,830
Other Finance Cost-3,495,830
Net Interest Income-3,495,830
 
Pretax Income (+$)
Operating Income16,671,020
Net Interest Income-3,495,830
Other Non-Operating Income Expenses0
Income Before Tax (EBT)8,684,51024,657,530
EBIT - interestExpense = 16,343,050
7,882,960
6,468,280
Interest Expense3,495,830
Earnings Before Interest and Taxes (EBIT)19,838,88012,180,340
Earnings Before Interest and Taxes (EBITDA)25,951,560
 
After tax Income (+$)
Income Before Tax8,684,510
Tax Provision-4,910,510
Net Income From Continuing Ops3,774,0003,774,000
Net Income2,972,450
Net Income Applicable To Common Shares2,972,450
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items4,669,610
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses110,583,310
Total Other Income/Expenses Net-7,986,5103,495,830
 

Technical Analysis of Glenmark Pharmaceuticals Limited
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Glenmark Pharmaceuticals Limited. The general trend of Glenmark Pharmaceuticals Limited is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Glenmark Pharmaceuticals Limited's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Glenmark Pharmaceuticals Limited.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: .

The bearish price targets are: 1,070 > 974.00 > 883.00.

Tweet this
Glenmark Pharmaceuticals Limited Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Glenmark Pharmaceuticals Limited. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Glenmark Pharmaceuticals Limited Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Glenmark Pharmaceuticals Limited. The current macd is 30.52.

The long score for the Moving Average Convergence/Divergence (MACD) is 2/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 0/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Glenmark Pharmaceuticals Limited price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Glenmark Pharmaceuticals Limited. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Glenmark Pharmaceuticals Limited price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Glenmark Pharmaceuticals Limited Daily Moving Average Convergence/Divergence (MACD) ChartGlenmark Pharmaceuticals Limited Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Glenmark Pharmaceuticals Limited. The current adx is 32.23.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Glenmark Pharmaceuticals Limited shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Glenmark Pharmaceuticals Limited Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Glenmark Pharmaceuticals Limited. The current sar is 1,018.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Glenmark Pharmaceuticals Limited Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Glenmark Pharmaceuticals Limited. The current rsi is 69.48. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Glenmark Pharmaceuticals Limited Daily Relative Strength Index (RSI) ChartGlenmark Pharmaceuticals Limited Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Glenmark Pharmaceuticals Limited. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Glenmark Pharmaceuticals Limited price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Glenmark Pharmaceuticals Limited Daily Stochastic Oscillator ChartGlenmark Pharmaceuticals Limited Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Glenmark Pharmaceuticals Limited. The current cci is 90.35.

Glenmark Pharmaceuticals Limited Daily Commodity Channel Index (CCI) ChartGlenmark Pharmaceuticals Limited Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Glenmark Pharmaceuticals Limited. The current cmo is 42.75.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Glenmark Pharmaceuticals Limited Daily Chande Momentum Oscillator (CMO) ChartGlenmark Pharmaceuticals Limited Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Glenmark Pharmaceuticals Limited. The current willr is -3.81599582.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Glenmark Pharmaceuticals Limited Daily Williams %R ChartGlenmark Pharmaceuticals Limited Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Glenmark Pharmaceuticals Limited.

Glenmark Pharmaceuticals Limited Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Glenmark Pharmaceuticals Limited. The current atr is 28.47.

Glenmark Pharmaceuticals Limited Daily Average True Range (ATR) ChartGlenmark Pharmaceuticals Limited Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Glenmark Pharmaceuticals Limited. The current obv is 120,601,617.

Glenmark Pharmaceuticals Limited Daily On-Balance Volume (OBV) ChartGlenmark Pharmaceuticals Limited Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Glenmark Pharmaceuticals Limited. The current mfi is 55.44.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Glenmark Pharmaceuticals Limited Daily Money Flow Index (MFI) ChartGlenmark Pharmaceuticals Limited Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Glenmark Pharmaceuticals Limited.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-01CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-07WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-12STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-14STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-03MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-31WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-07CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-09BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-14STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-15RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-07CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-12MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-21CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-27WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-01STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-04-03MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-24SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Glenmark Pharmaceuticals Limited Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Glenmark Pharmaceuticals Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5069.479
Ma 20Greater thanMa 501,015.818
Ma 50Greater thanMa 100948.454
Ma 100Greater thanMa 200901.572
OpenGreater thanClose1,036.000
Total4/5 (80.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Glenmark Pharmaceuticals Limited with someone you think should read this too:
  • Are you bullish or bearish on Glenmark Pharmaceuticals Limited? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Glenmark Pharmaceuticals Limited? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Glenmark Pharmaceuticals Limited

I send you an email if I find something interesting about Glenmark Pharmaceuticals Limited.


Comments

How you think about this?

Leave a comment

Stay informed about Glenmark Pharmaceuticals Limited.

Receive notifications about Glenmark Pharmaceuticals Limited in your mailbox!